Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

(2015) D. Jeffrey Newport et al.   AMERICAN JOURNAL OF PSYCHIATRY

The use of ketamine as an antidepressant: a systematic review and meta-analysis

(2015) Caoimhe M. Coyle et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent

(2015) SHELDON PRESKORN et al.   Journal of Psychiatric Practice

Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study

(2015) Y.-D. Hu et al.   PSYCHOLOGICAL MEDICINE

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION

(2014) Rebecca B. Price et al.   DEPRESSION AND ANXIETY

Do the dissociative side effects of ketamine mediate its antidepressant effects?

(2014) David A. Luckenbaugh et al.   JOURNAL OF AFFECTIVE DISORDERS

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

(2014) A. McGirr et al.   PSYCHOLOGICAL MEDICINE

Ketamine administration in depressive disorders: a systematic review and meta-analysis

(2014) Guillaume Fond et al.   PSYCHOPHARMACOLOGY

Pilot dose–response trial of i.v. ketamine in treatment-resistant depression

(2014) Rosalyn Lai et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

(2013) James W. Murrough et al.   AMERICAN JOURNAL OF PSYCHIATRY

The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders

(2013) Isabella Pacchiarotti et al.   AMERICAN JOURNAL OF PSYCHIATRY

Rapid antidepressant effects: moving right along

(2013) K Martinowich et al.   MOLECULAR PSYCHIATRY

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

(2013) G Sanacora et al.   MOLECULAR PSYCHIATRY

Ketamine for Depression: Where Do We Go from Here?

(2012) Marije aan het Rot et al.   BIOLOGICAL PSYCHIATRY

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

(2012) James W. Murrough et al.   BIOLOGICAL PSYCHIATRY

Ketamine for Treatment-Resistant Unipolar Depression

(2012) Sanjay J. Mathew et al.   CNS DRUGS

A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression

(2012) Sarah M. Szymkowicz et al.   JOURNAL OF AFFECTIVE DISORDERS

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder

(2011) Jordan R Covvey et al.   ANNALS OF PHARMACOTHERAPY

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

(2011) Gregory Luke Larkin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

(2010) Nancy Diazgranados et al.   ARCHIVES OF GENERAL PSYCHIATRY

Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

(2010) Nancy DiazGranados et al.   JOURNAL OF CLINICAL PSYCHIATRY

Treatment Options for Bipolar Depression

(2010) Eduard Vieta et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression

(2009) Rebecca B. Price et al.   BIOLOGICAL PSYCHIATRY

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

(2009) Marije aan het Rot et al.   BIOLOGICAL PSYCHIATRY

Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to anN-Methyl-D-Aspartate Antagonist

(2009) Rodrigo Machado-Vieira et al.   JOURNAL OF CLINICAL PSYCHIATRY

A regulatory Apologia — A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

(2008) Hans Melander et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

(2008) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

(2008) Gerard Sanacora et al.   NATURE REVIEWS DRUG DISCOVERY

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

(2008) Erick H. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE